[
  {
    "ts": "2025-09-27T04:59:09+00:00",
    "headline": "Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the most undervalued NASDAQ stocks to buy now. Citing momentum in Gilead Sciences, Inc. (NASDAQ:GILD)’s product pipeline, Moody’s updated the company’s outlook from stable to positive on September 18, maintaining the company’s A3 senior unsecured ratings. The forecast takes into account Gilead’s recent clearance by regulators and introduction of […]",
    "url": "https://finance.yahoo.com/news/gilead-sciences-gild-stock-sees-045909284.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "99c07b41-0f6b-3ec8-a44c-048507114c25",
      "content": {
        "id": "99c07b41-0f6b-3ec8-a44c-048507114c25",
        "contentType": "STORY",
        "title": "Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum",
        "description": "",
        "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) ranks among the most undervalued NASDAQ stocks to buy now. Citing momentum in Gilead Sciences, Inc. (NASDAQ:GILD)’s product pipeline, Moody’s updated the company’s outlook from stable to positive on September 18, maintaining the company’s A3 senior unsecured ratings. The forecast takes into account Gilead’s recent clearance by regulators and introduction of […]",
        "pubDate": "2025-09-27T04:59:09Z",
        "displayTime": "2025-09-27T04:59:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/b289a344cf46bb20faecd01ed5dc6107",
          "originalWidth": 240,
          "originalHeight": 160,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mRO6Vt56QsZVpg163jv5EQ--~B/aD0xNjA7dz0yNDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b289a344cf46bb20faecd01ed5dc6107.cf.webp",
              "width": 240,
              "height": 160,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zAmBXhGzahEZsMNHkCwDog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/b289a344cf46bb20faecd01ed5dc6107.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-stock-sees-045909284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-gild-stock-sees-045909284.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]